KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Non-Current Deffered Revenue (2018 - 2025)

Aurinia Pharmaceuticals' Non-Current Deffered Revenue history spans 4 years, with the latest figure at $12.6 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue rose 644.44% year-over-year to $12.6 million; the TTM value through Dec 2025 reached $12.6 million, up 644.44%, while the annual FY2025 figure was $12.6 million, 644.44% up from the prior year.
  • Non-Current Deffered Revenue reached $12.6 million in Q4 2025 per AUPH's latest filing, up from $12.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $12.6 million in Q4 2025 to a low of $1.7 million in Q4 2024.